Table 1.

Characteristics of the 184 Participants

Characteristics	All participants (N = 184)
Age in years, median (IQR)	15 (11–19)
Gender
Female, n (%)	104 (57)
Regimens before switch to TLD, n (%)
NNRTI-based regimens	115 (62.5)
PI-based regimens	68 (37)
InSTi-based regimens	1 (0.5)
VL before switch to TLD, n (%)
VL <1,000 copies/mL	139 (76)
VL ≥1,000 copies/mL	45 (24)
VL after switch to TLD, n (%)
VL <1,000 copies/mL	174 (95)
VL ≥1,000 copies/mL	10 (5)
Duration on TLD in months, median (IQR)	6.9 (5.5–9.1)

InSTi, integrase strand transfer inhibitor; IQR, interquartile range; NNRTI, non-nucleotide reverse transcriptase inhibitor; PI, protease inhibitor; TLD, tenofovir disoproxil fumarate/lamivudine/dolutegravir; VL, viral load.